Precision Biologics, Inc. announces new US Patent filing on optimized antibody PB-233

Precision Biologics announces the filing of a new patent for our second asset, PB-233. This antibody recognizes Core 2 O-Glycans of variant MUC5AC antigen. PB-233 recognizes numerous human solid tumors but does not react to normal healthy surrounding tissue. To utilize how PB-233 targets a new class of tumor specific antigens, Precision Biologics is developing an antibody drug conjugate (ADC) for purposes of treating patients with refractory solid tumors. Information regarding this new asset will be presented at an international recognized meeting in the Fall of 2024, at which time Precision Biologics will release this data publicly.